- Bone Marrow Transfusion/ Stem Cell Therapy
- Blood Transfusion
- Drug Therapy
Aplastic Anemia Market size was valued at USD 6,440.9 million in 2022 and is poised to grow at a CAGR of 5.2% over 2023-2029. Aplastic Anemia is a severe hematologic condition in which the body fails to make blood cells in sufficient numbers, causing a deficiency of all blood cell types, and is associated with cancer and various cancer syndromes. Based on the treatment type, drug therapy is anticipated to dominate the market share over the forecast period. According to a research report, aplastic anemia has an incidence of approximately 2 to 7 cases per million individuals per annum. The rise in the frequency of blood disorders globally and growing awareness will act as the growth drivers for the market, however, the high cost of treatment would be the lagging factor for the market. Growing demand for reliable and short treatment options, and increasing government support for research and development will be the opportunities for aplastic anemia market expansion.
Fastest Growing Market
The Aplastic Anemia and MDS International Foundation, National Organization for Rare Disorders and Cancer index are spreading awareness about aplastic anemia, for instance in Feb 2019, the Aplastic Anemia Trust spring awareness Campaign was launched. Furthermore, since May 2021, a clinical trial has been going on to assess the long-term efficacy and safety of Romiplostim in patients with aplastic anemia. Thus, the increased awareness, research and development and rapidly developing technology will lead to market growth within the forecast period.
The Aplastic Anemia market was valued at USD 6,440.9 million in 2022 and is expected to grow at a 5.2% CAGR over the forecast period 2023 – 2029.
Growing demand for reliable and short treatment options, and increasing government support for research and development will be the opportunities for aplastic anemia market expansion are the key opportunities for Aplastic Anemia market.
The rise in the frequency of blood disorders globally and growing awareness are the growth drivers in the Aplastic Anemia market.
Pfizer Inc., Bayer Ag, Novartis AG, Ligand Pharmaceuticals Incorporated, Genzyme Corporation, Mylan N.V., Biogen, Otsuka Pharmaceutical Co. Ltd., Regen BioPharma Inc., and BioLineRx are a few companies operating in the Aplastic Anemia market.